Follitropin Alfa (Gonal-F) Shortage: What Providers and Prescribers Need to Know in 2026

Intermittent follitropin alfa (Gonal-F) supply constraints have become a persistent operational challenge for fertility practices in 2026. While Gonal-F is not always listed on the FDA's official shortage database, real-world availability at retail and specialty pharmacies has been inconsistent — creating downstream disruptions to cycle scheduling, patient stress, and practice workflows.

This guide is intended for reproductive endocrinologists, fertility nurses, and prescribing staff managing patients on gonadotropin protocols. It covers the supply landscape, evidence-based protocol adjustments, alternatives, and strategies for proactive patient communication.

The Supply Landscape in 2026

Gonal-F (EMD Serono) remains the only FDA-approved follitropin alfa product in the United States. No biosimilar has received US approval, in contrast to Europe where Ovaleap and Bemfola provide competitive alternatives. Key supply factors driving ongoing constraints include:

Single US supplier with no generic backup — EMD Serono's manufacturing capacity has not fully kept pace with demand

Complex biologic manufacturing — CHO cell culture production is slow to scale and cannot respond rapidly to demand spikes

Growing ART demand — Expanding insurance mandates and demographic trends are driving a consistent increase in IVF cycle volume

Specialty-only distribution — Cold-chain requirements limit availability to specialty pharmacy channels, creating fewer access points

The 900 IU Redi-ject pen is most frequently unavailable; 300 IU and 450 IU pens and the multi-dose vials (450 IU, 1050 IU) tend to have better availability.

Clinical Protocol Adjustments During Shortage Conditions

When follitropin alfa supply is constrained, the following protocol adjustments are supported by clinical evidence and widely used in practice:

Switching to Follistim AQ (Follitropin Beta)

Follistim AQ (follitropin beta, Organon) is the most evidence-supported alternative. Multiple randomized controlled trials and meta-analyses have shown comparable clinical outcomes between follitropin alfa and follitropin beta, including equivalent numbers of oocytes retrieved, fertilization rates, and clinical pregnancy rates. Dosing is not identical on a 1:1 basis — prescribers should review current formulary guidance when converting.

UnitedHealthcare, through its Optum Fertility Solutions program, approves Follistim AQ, Gonal-F, Gonal-F RFF, and Menopur interchangeably for ovulation induction, controlled ovarian stimulation, and ART indications, subject to medical necessity criteria. Most major payers treat these medications similarly; however, a new prior authorization may be required when switching.

Switching to or Adding Menopur (Menotropins)

Menopur (menotropins, Ferring) contains both FSH and LH activity, making it pharmacologically distinct from pure FSH products. Many reproductive endocrinologists use Menopur-based or combination protocols effectively. If switching fully from Gonal-F to Menopur, supplemental LH activity is already incorporated. If adding Menopur to reduce Gonal-F volume, protocol recalculation is required. Monitor estradiol and follicular response carefully at the start of any Menopur-based protocol.

Adjusting Prescription Format

Before switching medications entirely, consider whether a change in Gonal-F format can resolve the supply issue. The multi-dose vials (450 IU and 1050 IU) require reconstitution and more complex administration for patients, but availability is often better than the pen formats. Patient education and a brief demonstration from nursing staff can make this transition manageable for motivated patients.

Practice-Level Supply Chain Strategies

Practices that have navigated follitropin alfa shortages most successfully tend to have the following in place:

Relationships with multiple specialty pharmacies. Don't rely on a single preferred pharmacy. Cultivate relationships with Freedom Fertility, Encompass Rx, Alto Pharmacy, and Village Fertility Pharmacy.

In-house or clinic-affiliated dispensary. A growing number of practices are establishing dispensary capabilities to control medication access for their patients.

Early prescription issuance. Write prescriptions at least 2 weeks before anticipated cycle start dates to allow adequate lead time for pharmacy sourcing.

Direct EMD Serono contact. Providers can call EMD Serono's Fertility Lifelines (1-866-538-7879) for assistance locating stock through their distribution network.

Patient Communication Recommendations

Proactive communication reduces patient anxiety and last-minute scrambles. Consider:

Informing patients at the cycle planning visit that Gonal-F availability can be variable and advising them to begin sourcing early

Providing a list of preferred specialty pharmacies with contact numbers in patient discharge materials

Having a pre-planned alternative protocol ready so staff can respond quickly without delays to cycle timing

Direct patients to medfinder for providers — a service where patients enter their medication and location and medfinder contacts pharmacies on their behalf to find available stock. It's a practical tool to recommend patients use before calling you in a panic. See also our provider guide to helping patients find Gonal-F for more practice-level recommendations.